Adequan is a chronic joint pain supportive medication. Pets that benefit from Adequan typically show increased mobility, decreased pain, and overall improvement in arthritis symptoms. This improvement can take several weeks to appreciate. In cats, Adequan is one of the safest available arthritis management tools available. Very rarely, pets are sore at the site of injection for a short period after administration. This is much less likely with subcutaneous injection.
50-100 pound dog $55.00-$76.00/injection; after first 2-3 weeks typically will teach owner to administer at home which greatly decreases expense.
Adequan (polysulfated GAGs) GAGs are building materials for joints, have anti-inflammatory properties of their own that help slow down the actual damage to the cartilage, and they help the joints create more lubricating fluid. Prescribed in significant quantities at first, dosage decreases over time: given as an injection twice weekly for 4 weeks, once weekly for 4 weeks, every other week for 4 doses, every third week for 4 weeks, then once monthly for life.
Adequan is an injectable polysulfatated glycosaminoglycan (PSGAG or GAG). In common terms, it is an injectable medication that when given regularly, acts as a lubricant and inhibitor of proteins that damage joint cartilage. Adequan provides the joints with chondroitin, a GAG that helps with compression in the joint. It also allows for production of collagen which helps create building blocks to make new cartilage. In summary, Adequan protects and helps rebuild joints slowing down the development of osteoarthritis
Recommended product: Cosamin DS, purchased at Costco or Sams, 230 count, 1500 mg capsules, $59.99, 50-100 pounds take 1 capsule orally daily, $0.26/day
Gabriella Varcoe, Julia Tomlinson, Jane Manfredi; Owner Perceptions of Long-Term Systemic Use of Subcutaneous Administration of Polysulfated Glycosaminoglycan. J Am Anim Hosp Assoc 1 September 2021; 57 (5): 205–211. doi: https://doi.org/10.5326/JAAHAMS-7101
Polysulfated glycosaminoglycan (PSGAG) is a slow-acting disease-modifying agent used to treat degenerative joint disease. Although labeled for intramuscular use, it is commonly given by owners via a subcutaneous (SC) route. There is little information on adverse events related to SC administration or what other therapies are used concurrently with PSGAG. We hypothesized that SC PSGAG is perceived by owners as having minimal adverse events and that it would most often be given with other therapies. Owners (n = 378) were surveyed about their perceptions regarding SC PSGAG prescribed to dogs at one veterinary rehabilitation clinic. Complete surveys were provided for 69 dogs (two owners had multiple dogs). Overall, 13/69 (18.8%) dogs had an adverse event reported during the use of PSGAG. Most events were considered minor (stomach upset, loose stool, pain at injection site, fear) and did not lead to discontinuation of PSGAG. One dog experienced a moderate adverse event (persistent gastrointestinal symptoms) and one a severe adverse event (thrombocytopenia, bruising), which resolved after discontinuing PSGAG. PSGAG is most commonly administered along with other medications and rehabilitation therapies. The present study demonstrates that SC administration of PSGAG is well tolerated in most of the dogs, with primarily mild, self-resolving adverse events. © 2021 by American Animal Hospital Association2021 You do not currently have access to this content.
FAQ
Can you give Adequan subcutaneous?
Where is Adequan injected in dogs?
Does Adequan go IM?
Can you give too much Adequan?
Overdose of Polysulfated Glycosaminoglycan (Adequan) is rare but could cause: Joint Pain. Swelling. Lameness.